IDYA

IDEAYA Biosciences, Inc.

Tremor tracks 6 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

IDYAIDEAYA Biosciences
0Calm
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Signing up patientsPhase 3450 patientsMain results: Mar 2034
IDYAIDEAYA Biosciences
0Calm
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Signing up patientsPhase 1/2262 patientsMain results: Jul 2029
IDYAIDEAYA Biosciences
0Calm
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Signing up patientsPhase 1/2336 patientsMain results: Jan 29, 2027
IDYAIDEAYA Biosciences
0Calm
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Signing up patientsPhase 3520 patientsMain results: Oct 2030
IDYAIDEAYA Biosciences
0Calm
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Running, no new patientsPhase 2160 patientsMain results: Apr 30, 2027
IDYAIDEAYA Biosciences
0Calm
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Running, no new patientsPhase 2/3420 patientsMain results: Jan 15, 2027

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

3 sales (0 not pre-planned) · 0 purchases

Hata Yujiro SPresident and CEO · Oct 6, 2026Sold 25,538 sharesabout $955 thousand · pre-planned
Hata Yujiro SPresident and CEO · Oct 6, 2026Sold 800 sharesabout $31 thousand · pre-planned
Ruiz Briseno AndresChief Accounting Officer · Jul 7, 2026Sold 9,550 sharesabout $382 thousand · pre-planned

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.